Assay What? Tysabri's PML Woes Could Find Partial Fix
Some of the world's best scientific brains were gearing up for the American Academy of Neurology meeting this week in Toronto, and among the hoped-for data to tumble out of sessions are details of Biogen Idec Inc.'s approach to using an iffy but promising method of weeding out likely PML cases from multiple sclerosis patients.
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.